Sub Lingual Misoprostol Before IUD Insertion in Women With Only Previous Cesarean Section
SUB LINGUAL MISOPROSTOL PRIOR TO IUD INSERTION IN WOMEN WITH ONLY PREVIOUS CESARIAN SECTION: A Randomized Controlled Trial
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt
- Ain Shams University Maternity Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Normal size uterus.
- Willing to participate.
- Candidate for IUD insertion.
- Delivered only by cesarean section.
- Last delivery is more than 40 days before participating in the study.
Exclusion Criteria:
- Previous vaginal delivery
- Signs of genital infection.
- Menopause.
- Body mass index (BMI) > 35 kg/m2.
- Contraindication to misoprostol.
- Copper allergy.
- Positive pregnancy test.
- Had a prior attempt for IUD insertion.
- Uterine anomalies.
- Uterine fibroid.
Study Plan
How is the study designed?
Design Details
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: Misoprostol
Women will receive two sub lingual tablets each containing 200 micro gram misoprostol (Misotac), receiving a total dose of 400 micro grams.
Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
|
Other Names:
|
|
PLACEBO_COMPARATOR: Placebo
Women will receive two sub lingual placebo tablets which will be similar in size, color, odor and shape to the misoprostol tablets.
Two hour later, Cu T 380A IUD (PREGNA) will be inserted.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain
Time Frame: During the procedure
|
The perception of pain and discomfort as described by the patient assessed by Visual Analogue Scale (VAS).
The scale will be graded from 0 to 10, 0 representing no pain at all and 10 worst possible imaginable pain.
|
During the procedure
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Difficulty of Procedure
Time Frame: During the procedure
|
The degree of difficulty of the IUD insertion judged by the investigator as the resistance met at the internal cervical os.
The procedure either graded as (easy), (moderate difficulty) or (difficult) or (failed insertion).
|
During the procedure
|
|
Complications
Time Frame: During the procedure and the following 24 hours.
|
Uterine perforation, excessive bleeding, fever, IUD expulsion or any other unexpected complications will be assessed during the procedure and followed for the next 24 hours.
|
During the procedure and the following 24 hours.
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Hassan A. Bayoumy, Professor, Ain Shams University
- Principal Investigator: Mohamed Y. Mohamed, M.B., B.Ch., Assiut University
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 9010023
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.